Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Giada Bianchi.
Connection Strength

5.810
  1. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 Jul; 2(4):338-353.
    View in: PubMed
    Score: 0.972
  2. Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J. 2019 Jan/Feb; 25(1):11-18.
    View in: PubMed
    Score: 0.818
  3. Promising therapies in multiple myeloma. Blood. 2015 Jul 16; 126(3):300-10.
    View in: PubMed
    Score: 0.638
  4. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014 Nov-Dec; 64(6):422-44.
    View in: PubMed
    Score: 0.609
  5. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jul 10; 32(20):2125-32.
    View in: PubMed
    Score: 0.595
  6. Multiple Myeloma Cells Depend on the DDI2/NRF1-mediated Proteasome Stress Response for Survival. Blood Adv. 2021 Oct 14.
    View in: PubMed
    Score: 0.248
  7. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
    View in: PubMed
    Score: 0.242
  8. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
    View in: PubMed
    Score: 0.240
  9. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev. 2020; 5(2):67-85.
    View in: PubMed
    Score: 0.221
  10. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209.
    View in: PubMed
    Score: 0.210
  11. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma. 2018 03; 59(3):542-561.
    View in: PubMed
    Score: 0.184
  12. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.159
  13. The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014 Jan; 28(1):45-53.
    View in: PubMed
    Score: 0.145
  14. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
    View in: PubMed
    Score: 0.112
  15. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
    View in: PubMed
    Score: 0.108
  16. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26; 113(13):3040-9.
    View in: PubMed
    Score: 0.103
  17. Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008 Oct 21; 9 Suppl 1:S1.
    View in: PubMed
    Score: 0.101
  18. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
    View in: PubMed
    Score: 0.057
  19. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.